Skip to main content
Article thumbnail
Location of Repository

An alternative approach to measuring treatment persistence with antipsychotic agents among patients with schizophrenia in the Veterans Health Administration

By Xinhua S Ren, Shirley Qian and Lewis E Kazis

Abstract

Prior studies have demonstrated the importance of treatment persistence with anti-psychotic agents in sustaining control of schizophrenic symptoms. However, the conventional approach in measuring treatment persistence tended to use only the first prescription episode even though some patients received multiple prescriptions (or multiple treatment episodes) of the same medication within one year following the initiation of the index drug. In this study, we used data from the Veterans Health Administration in the United States to assess the extent to which patients received multiple prescriptions. The study found that about a quarter of the patients had two or more treatment episodes and that levels of treatment persistence tended to vary across treatment episodes. Based on these results, we offered an alternative approach in which we calculated treatment persistence with typical and atypical antipsychotic agents separately for patients with one, two, or three treatment episodes. Considering that patients with different number of treatment episodes might differ in disease profiles, this treatment episode-specific approach offered a fair comparison of the levels of treatment persistence across patients with different number of treatment episodes. Future research needs to extend the analyses beyond two antipsychotic classes to individual antipsychotic agents. A more comprehensive assessment using appropriate analytic methods should help physicians make prescription choices that will ultimately improve the care of patients with schizophrenia

Topics: Original Research
Publisher: Dove Medical Press
OAI identifier: oai:pubmedcentral.nih.gov:2654631
Provided by: PubMed Central

Suggested articles

Citations

  1. (2002). A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia.
  2. (2003). A comparison of adherence and persistence levels among schizophrenia patients treated with atypical antipsychotics. Schizophr Res,
  3. (1999). Anti-psychotic-induced weight gain: A comprehensive research synthesis.
  4. (2003). Antipsychotic maintenance in schizophrenia: partial compliance and clinical outcome. Schizophr Res,
  5. (2002). Antipsychotic medication adherence: Is there a difference between typical and atypical agents?
  6. (1998). At issues: Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.
  7. (2003). Atypical antipsychotic adherence and hospitalization in patients with schizophrenia. Schizophr Res,
  8. (1996). Drug therapy: schizophrenia.
  9. (1991). Effect of health education in promoting prescription refi ll compliance among patients with hypertension. Clin Ther,
  10. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
  11. (2001). Effectiveness of second-generation anti-psychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials.
  12. (2002). Effects of antipsychotic partial compliance on resource utilization in a schizophrenia and bipolar population [abstract].
  13. (1999). Effi cacy and extrapyramidal effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a metaanalysis of randomized controlled trials. Schizophr Res,
  14. (2002). Effi cacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
  15. (1999). Enhancing medication compliance for people with serious mental illnesses.
  16. (1997). Factors infl uencing relapse in the long-term course of schizophrenia. Schizophr Res,
  17. (2002). Health Administration.
  18. (2001). Improving patient adherence: state of the art, with a special focus on medication taking for cardiovascular disorders.
  19. (2004). Initiation of atypical antipsychotic agents and health outcomes in patients with schizophrenia.
  20. Ment Dis,
  21. (2000). Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for Research in Schizophrenia. Arch Gen Psychiatry,
  22. (2002). Optimal dosing of atypical anti-psychotics in adults: A review of the current evidence. Harvard Rev Psychiatry,
  23. (2003). Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia.
  24. (2005). Patients’ characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia.
  25. (2002). Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care,
  26. (2002). Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of literature.
  27. (1997). Psychiatric Association.
  28. (2001). Refi ll patterns of atypical and conventional antipsychotic medications at a national retail pharmacy chain. Psychiatr Serv,
  29. (1999). The association of medical comorbidity in schizophrenia with poor physical and mental health.
  30. (1996). The organizational structure for medical information management in the Department of Veterans Affairs: an overview of major health care databases. Med Care,
  31. (1997). The road back: working with the severely mentally ill.
  32. (2004). The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations
  33. (2003). Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv,
  34. (2006). Treatment persistence: A comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents.
  35. (2001). Use of pharmacy data to assess quality of pharmacotherapy for schizophrenina in a national health care system: individual and facility predictors. Med Care,
  36. (1999). Use patterns for antipsychotic medications in Medicaid patients with schizophrenia.
  37. (2001). Using Drug Claims
  38. (2001). Utility of a transdermal delivery system for antihypertensive therapy. Part 2.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.